Nicotinamide adenine dinucleotide (NAD) supplements have gained attention for their potential role in cellular energy production and age-related health. NAD+ is a vital coenzyme involved in metabolism, DNA repair, and cellular function, with levels naturally declining as we age. Supplements containing NAD+ precursors—such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—aim to restore these levels. Whilst preclinical research shows promise, human clinical evidence remains limited and inconsistent. This article examines the evidence-based benefits of NAD supplementation, who might consider it, and important safety considerations for UK patients.

What Is NAD and How Does It Work in the Body?

Nicotinamide adenine dinucleotide (NAD) is a coenzyme found in every living cell, playing a fundamental role in cellular metabolism and energy production. NAD exists in two forms: NAD+ (oxidised) and NADH (reduced), which work together in redox reactions essential for converting nutrients into cellular energy through processes such as glycolysis and the citric acid cycle.

Beyond energy metabolism, NAD+ serves as a crucial substrate for several enzyme families, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38. Sirtuins regulate gene expression, DNA repair, and cellular stress responses, whilst PARPs are involved in maintaining genomic stability. These NAD+-dependent enzymes influence processes ranging from circadian rhythm regulation to inflammatory responses and cellular ageing.

NAD+ levels naturally decline with age, a phenomenon observed across multiple tissues and linked to various age-related physiological changes. This decline occurs due to increased consumption by NAD+-dependent enzymes, reduced biosynthesis, and enhanced degradation. The body synthesises NAD+ through multiple pathways: the de novo pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide—the latter being the primary route in mammals.

NAD+ precursors include nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide (NAM), and nicotinic acid (NA). These compounds are converted into NAD+ through different enzymatic pathways, with varying efficiency and tissue distribution. It's important to note that in Great Britain, NR (nicotinamide riboside chloride) is authorised as a novel food with specific conditions including a maximum adult daily intake of 300 mg, while NMN is not authorised for use in foods or supplements under current novel food regulations.

Evidence-Based Benefits of NAD Supplements

Research into NAD+ supplementation has expanded considerably, though most robust evidence derives from preclinical studies, with human clinical data still emerging. Cellular energy metabolism represents the most established area, with NAD+ precursors demonstrating capacity to enhance mitochondrial function in animal models. Studies suggest potential improvements in oxidative metabolism and ATP production, particularly in contexts of metabolic stress or ageing.

In the realm of metabolic health, human trials of nicotinamide riboside have shown inconsistent results. Multiple randomised controlled trials in overweight, obese or insulin-resistant adults have found no meaningful improvement in insulin sensitivity or glycaemic control. While some studies suggest possible benefits, these signals require confirmation in larger trials before clinical recommendations can be made.

Neuroprotection has garnered significant research interest, with animal studies suggesting NAD+ precursors may support neuronal health and cognitive function. Mechanisms proposed include enhanced mitochondrial function in neurons, reduced oxidative stress, and activation of neuroprotective sirtuins. Small human studies have explored cognitive outcomes, but evidence remains insufficient to support specific clinical recommendations.

Regarding cardiovascular health, a small randomised controlled trial published in Science Translational Medicine reported improvements in arterial stiffness and blood pressure in middle-aged adults taking nicotinamide riboside. However, these findings were from a short-duration study with a limited sample size and require replication in larger, longer-term trials before clinical recommendations can be made.

Anti-ageing effects remain largely theoretical in humans. Whilst NAD+ precursors activate longevity-associated pathways in laboratory models, translating these findings to human healthspan or lifespan extension lacks substantive clinical evidence. There are no authorised health claims in the UK for NAD+ supplements relating to anti-ageing, metabolism, cognition or cardiovascular outcomes under the GB Nutrition and Health Claims Register.

Who Might Benefit from NAD Supplementation?

Identifying appropriate candidates for NAD+ supplementation requires careful consideration of current evidence limitations and individual health status. Older adults represent a theoretically relevant population, given the documented age-related decline in NAD+ levels. However, whether supplementation meaningfully impacts functional outcomes, quality of life, or disease risk in healthy ageing individuals remains unestablished through rigorous clinical trials.

Individuals with metabolic syndrome or prediabetes have been studied in clinical trials, but the evidence for benefit remains inconsistent. Any use in these conditions should be considered investigational and not a replacement for established interventions such as dietary modification, physical activity, and weight management as recommended by NICE guidelines. NAD+ supplementation is not currently recommended by NICE or other UK clinical bodies for metabolic conditions.

People experiencing chronic fatigue or mitochondrial dysfunction sometimes explore NAD+ supplementation, though evidence supporting efficacy in these conditions is limited. Whilst the theoretical rationale exists—given NAD+'s role in cellular energy production—clinical validation is lacking. Individuals with persistent fatigue should undergo appropriate medical evaluation in line with NICE guidance (NG206 for ME/CFS) to exclude underlying conditions such as thyroid disorders, anaemia, sleep apnoea, or red flag symptoms (unintentional weight loss, fevers, chest pain, breathlessness, neurological deficits) before attributing symptoms to NAD+ deficiency.

Athletes and physically active individuals may be interested in potential performance or recovery benefits. Some preliminary research suggests NAD+ precursors might influence exercise metabolism and muscle function, but evidence is insufficient to recommend routine supplementation for performance enhancement.

Importantly, NAD+ supplementation is not recommended for pregnant or breastfeeding women due to insufficient safety data, children and adolescents under 18 (in line with novel food authorisation conditions for NR), or individuals with active malignancy without oncology consultation, given NAD+'s role in cell proliferation. Anyone considering supplementation should consult their GP or a registered healthcare professional, particularly those with existing medical conditions or taking prescribed medications.

Safety, Side Effects and Dosage Considerations

NAD+ precursor supplements generally demonstrate good tolerability in clinical trials, with most adverse effects being mild and transient. The safety profile varies somewhat between different precursors, with nicotinamide riboside showing a favourable profile in studies to date.

Common side effects reported include:

• Gastrointestinal symptoms: nausea, diarrhoea, abdominal discomfort, and bloating, typically dose-dependent and resolving with continued use or dose reduction

• Flushing: particularly with nicotinic acid (niacin), due to prostaglandin-mediated vasodilation; less common with other NAD+ precursors

• Headache: reported occasionally, usually mild and self-limiting

• Fatigue or insomnia: some individuals report changes in energy levels or sleep patterns, possibly related to effects on circadian rhythm regulation

Doses used in research vary by precursor type. Clinical trials have typically used:

• Nicotinamide riboside: 250–1,000 mg daily (note: in Great Britain, NR is authorised as a novel food with a maximum adult daily intake of 300 mg)

• Nicotinamide mononucleotide: 250–500 mg daily (note: NMN is not authorised for use in foods or supplements in Great Britain under current novel food regulations)

• Nicotinamide: 250–500 mg daily (UK Expert Group on Vitamins and Minerals guidance level is 500 mg/day)

Consumers should not exceed product label directions or established upper levels. High-dose supplementation should only occur under medical supervision.

Drug interactions and safety concerns include:

• High-dose nicotinic acid may cause hepatotoxicity (especially sustained-release forms), worsen glycaemic control, raise uric acid levels (potentially precipitating gout), and increase myopathy risk when taken with statins

• Niacin can potentiate hypotension when taken with antihypertensive medications

• Theoretical interactions with medications affecting methylation pathways may occur, though clinical significance is uncertain

Long-term safety data remains limited, with most trials lasting weeks to months rather than years. While theoretical concerns exist about potential effects on cancer risk given NAD+'s role in cell proliferation, no evidence currently supports increased malignancy risk in humans.

Patients should contact their GP if they experience persistent gastrointestinal symptoms, unexplained fatigue, significant sleep disturbance, or any concerning symptoms after starting supplementation. Those with pre-existing liver or kidney disease require medical supervision, as these organs play crucial roles in NAD+ metabolism and precursor clearance.

Suspected adverse reactions to supplements can be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions